Venturi Wealth Management LLC Has $114,000 Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Venturi Wealth Management LLC grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 602.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 344 shares of the company’s stock after acquiring an additional 295 shares during the period. Venturi Wealth Management LLC’s holdings in Medpace were worth $114,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Centaurus Financial Inc. raised its position in shares of Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after buying an additional 29 shares in the last quarter. Lindenwold Advisors INC raised its position in shares of Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after buying an additional 32 shares in the last quarter. Stephens Inc. AR raised its position in shares of Medpace by 4.9% in the fourth quarter. Stephens Inc. AR now owns 752 shares of the company’s stock valued at $250,000 after buying an additional 35 shares in the last quarter. M&T Bank Corp raised its position in shares of Medpace by 1.2% in the third quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock valued at $1,068,000 after buying an additional 37 shares in the last quarter. Finally, Custom Index Systems LLC raised its position in shares of Medpace by 3.0% in the fourth quarter. Custom Index Systems LLC now owns 1,290 shares of the company’s stock valued at $429,000 after buying an additional 37 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average target price of $381.44.

Medpace Stock Performance

NASDAQ MEDP opened at $340.78 on Friday. The firm’s fifty day moving average price is $343.13 and its two-hundred day moving average price is $347.20. The stock has a market cap of $10.38 billion, a PE ratio of 26.98, a PEG ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.